Our mRBC-aAPCs, comprised of membrane-bound 4-1BBL and IL-12, retained a favorable safety profile demonstrated by no significant changes in mice body weight and minimal, reversible changes in splenomegaly, liver inflammation, ALT elevations, and IFNγ levels (Fig. 2b–d and Supplementary Fig. 5). This evidence concerns the gene IFNG and Splenomegaly.